Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.13
Bid: 2.06
Ask: 2.20
Change: 0.00 (0.00%)
Spread: 0.14 (6.796%)
Open: 2.10
High: 0.00
Low: 0.00
Prev. Close: 2.13
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directors' Dealings

23 Jul 2009 16:17

RNS Number : 2020W
Immupharma PLC
23 July 2009
 



For Immediate Release

23 July 2009

ImmuPharma PLC

Directors' Dealings

Institutions increase stake

 

ImmuPharma PLC ('ImmuPharma' or the 'Company') (LSE:IMM) announces that a number of existing and new blue-chip institutional investors have purchased shares from Richard Warr and the Trusts of Richard Warr and Dimitri Dimitriou, who are two of ImmuPharma's founders and Directors.  A total of 12.5 million ordinary shares (16.1% of the issued share capital) of 10 pence each in the Company, were placed by Noble & Company Limited at a price of 86 pence per share to institutional investors on 23 July 2009. Panmure Gordon is the NOMAD and Corporate Broker to the Company. 

 

Following the disposal, the current holdings directly or through Trust are:

Ordinary Shares Sold

Ordinary Shares Retained

Percentage  of shares in issue

Richard Warr (1)

6,250,000

3,528,968

4.6%

Dimitri Dimitriou (2)

6,250,000

3,528,969

4.6%

Dr Zimmer & Family

0

23,056,602

29.8%

 

(1)  Ordinary shares of £0.10 held by Louvre Trustees Limited where the Warr family has a beneficial interest and shares held directly by Richard Warr

 

(2)  Ordinary shares of £0.10 held by Louvre Trustees Limited where the Dimitriou family has a beneficial interest. 

 

Richard Warr, ImmuPharma's Chairman said: "We are delighted with the support received from our existing investors and the demand from new investors including M&G Investments.  The allocation of these shares further increases ImmuPharma's free float with the aim of improving overall liquidity."

 

For further information please contact: 

ImmuPharma PLC

+44 20 7152 4080

Dimitri Dimitriou, Chief Executive Officer 

Richard Warr, Chairman

Panmure Gordon

+44 151 243 0963

Andrew Burnett/ Rakesh Sharma 

Noble & Company Limited

+44 20 7763 2335

John Millar

Buchanan Communications

+44 20 7466 5000

Lisa Baderoon 

Rebecca Skye Dietrich

More information on the Company can be found at www.immupharma.com 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSSELFIDSUSEFW
Date   Source Headline
7th Feb 20077:01 amRNSBoard Changes
19th Jan 20078:57 amRNSTotal Voting Rights
5th Jan 20072:27 pmRNSIssue of Equity
27th Dec 20062:53 pmRNSTotal Voting Rights
21st Dec 20067:01 amRNSIssue of Equity
30th Oct 20067:01 amRNSFurther Phase II Data
17th Oct 20067:00 amRNSPhase II Data
2nd Oct 20067:01 amRNSFDA Meeting on Lupus
26th Sep 20067:01 amRNSInterim Results
1st Aug 20067:01 amRNSPreliminary Results
5th Jul 20067:00 amRNSStart of phase II trial
12th Jun 20065:04 pmRNSAccounting reference dates
10th May 20067:00 amRNSPhase 1 Lupus results
11th Apr 20067:00 amRNSResearch Grants
15th Feb 20061:56 pmRNSResult of EGM and Placing
24th Jan 20064:30 pmRNSSch 1 Update - ImmuPharma plc
23rd Jan 20064:27 pmRNSCirc re. ImmuPharma posted
30th Nov 20051:38 pmRNSInterim Results
27th May 20051:29 pmRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.